Avanir Pharmaceuticals (NASDAQ: AVNR)

Avanir Pharmaceuticals (NASDAQ: AVNR) is dedicated to acquiring, developing, and commercializing innovative therapeutic products designed to treat chronic diseases. Zenvia™, the company’s lead product candidate, is currently being developed to treat pseudobulbar affect (PBA). GlaxoSmithKline Consumer Healthcare currently markets Avanir’s first commercialized product, Abreva®, in North America. Abreva is the leading over-the-counter product for the treatment of cold sores. For further information, visit the Company’s web site at www.avanir.com.